Browse the evidence

Micellar casein provides a sustained, slow-release amino acid profile, whereas free L-amino acids (L-AAs) and casein glycomacropeptide (CGMP) result in rapid, transient absorption peaks.

If you want a slow, steady drip of amino acids (like before bed or during long fasting windows), choose micellar casein. If you need a rapid spike of amino acids (like immediately post-workout), free amino acids or CGMP will deliver them much faster than casein. Note that CGMP does not act like casein despite being a peptide.

Visceral adipose tissue (VAT) accumulation exacerbates insulin resistance and increases fasting blood glucose and HbA1c, whereas brown adipose tissue (BAT) activation improves glucose regulation and insulin sensitivity.

Focus on reducing visceral fat (belly fat) rather than just total body weight. Strategies that activate brown fat (like cold exposure or specific exercises) or reduce visceral fat (through diet/exercise) are more effective for blood sugar control than general weight loss alone.

Visceral fat and epicardial fat are primary drivers of cardiovascular disease pathology through inflammatory and vasocrine signaling, whereas subcutaneous lower-body fat may be protective.

Focus on reducing belly fat (visceral fat) rather than just total weight. Measure your waist circumference. If it is high, prioritize lifestyle changes that target visceral fat, as this specific fat drives heart disease through inflammation.

Ketogenic diets improve specific biochemical markers (HDL, Triglycerides, Insulin) compared to control diets, even when weight loss outcomes are similar.

Even if you don't lose more weight than on a low-fat diet, switching to a ketogenic diet may improve your blood lipid profile and insulin sensitivity.

Selective reduction of dietary fat (but not carbohydrate) in adults with obesity decreases striatal dopamine D2/3 receptor binding potential and neural activity to food cues, leading to increased consumption of hyperpalatable foods high in both fat and carbohydrate.

If you are trying to lose weight by cutting fat, be aware that your brain may biologically respond by increasing the 'reward signal' (dopamine) for high-fat, high-carb foods. This doesn't mean you lack willpower; it means your brain is signaling a stronger desire for those specific foods. To counter this, you might need to be extra mindful of hyperpalatable foods (high sugar + high fat) when following a low-fat diet, as your brain may be primed to seek them out more aggressively than if you had restricted carbohydrates instead.

GLP-1 receptor agonists (specifically high-dose liraglutide) prevent the progression from prediabetes to type 2 diabetes in obese individuals.

If you have prediabetes and are overweight, talk to your doctor about GLP-1 medications like liraglutide. They can significantly reduce your risk of developing full-blown type 2 diabetes.

Incretin-based treatments (semaglutide, dulaglutide) are effective and safe in adolescents with obesity or type 2 diabetes.

For teenagers with obesity or type 2 diabetes, weekly injections of semaglutide or dulaglutide can significantly improve weight and blood sugar control. Side effects like nausea are common but usually mild and go away quickly.

Shorter duration of hypertension history is an independent predictor of hypertension remission following Roux-en-Y gastric bypass surgery, with each additional year of history decreasing the odds of remission by approximately 15%.

If you are considering bariatric surgery to get off blood pressure medication, the length of time you have had high blood pressure matters. The study shows that for every year you wait, your chances of successfully stopping medication drop by about 15%. This suggests that addressing hypertension early, or seeking surgical options sooner rather than later, offers the best chance for remission.

GLP-1 receptor agonists (Liraglutid, Semaglutid) and dual agonists (Tirzepatid) produce significant weight loss (16-20%) and reduce cardiovascular/renal complications in Type 2 Diabetes, but their long-term efficacy and cost-effectiveness remain unproven.

If lifestyle changes are insufficient, GLP-1 drugs like Semaglutid offer significant weight loss (up to 20%) and heart/kidney benefits, especially for diabetics. However, they are expensive, require injections, and likely need to be taken indefinitely to maintain weight loss. Discuss cost and long-term commitment with your doctor.

SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100 demonstrate varying degrees of efficacy in weight management, with SGLT-2 inhibitors showing mild but significant weight loss in non-diabetic obese patients.

Several other medications besides GLP-1 agonists can help with weight loss, including SGLT-2 inhibitors, orlistat, phentermine/topiramate, metformin, tirzepatide, and Gelesis100. Their effectiveness varies, with some showing significant weight loss and others showing mild but significant benefits. These options provide additional choices for patients who may not be candidates for or respond poorly to GLP-1 agonists.

SGLT2 inhibitors (specifically enavogliflozin and sotagliflozin) provide superior glycemic control and cardiovascular/renal benefits compared to placebo or standard care in patients with type 2 diabetes, with sotagliflozin specifically indicated for heart failure.

If you have type 2 diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors like sotagliflozin or enavogliflozin. These oral drugs are now prioritized in guidelines because they protect your heart and kidneys while lowering blood sugar.

GLP-1 receptor agonists (specifically semaglutide) produce substantial, sustained weight loss and improve health status in patients with heart failure with preserved ejection fraction (HFpEF).

For patients with HFpEF and obesity, GLP-1 agonists like semaglutide are a potent tool for weight loss and improving heart function. This treatment, combined with dietary advice, can lead to significant health improvements. Discuss this option with your cardiologist, especially if other weight loss methods have been difficult to sustain.

Visceral obesity is a critical risk factor for cardiovascular disease, often present in individuals with normal BMI, leading to underestimation of cardiovascular risk in clinical practice.

Don't rely solely on BMI. If you have a family history of heart disease, ask for a waist circumference measurement or visceral fat assessment, as 'normal weight' obesity can still cause heart attacks.

Tirzepatide (dual GLP-1/GIP agonist) produces superior weight loss compared to semaglutide in patients with type 2 diabetes.

For patients with type 2 diabetes, tirzepatide (5-15 mg weekly) may offer better weight loss (8.5-12.4%) than semaglutide (6.7%). However, it is not yet registered for obesity treatment in Poland, so access may be limited.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces greater weight loss than Semaglutide in patients with type 2 diabetes.

If you have type 2 diabetes and obesity, ask your doctor about Tirzepatide. It is a once-weekly injection that combines two hormones to help you lose more weight than Semaglutide. It starts at a low dose and increases every few weeks to reach the maximum dose.

Tirzepatide provides significant cardiovascular, hepatic, and renal benefits in obese patients, including improved lipid profiles, reduced blood pressure, and potential protection against NAFLD/NASH and CKD progression.

Beyond weight loss, Tirzepatide improves heart health by lowering blood pressure and cholesterol, and may protect the liver (NAFLD/NASH) and kidneys (CKD). These benefits are observed alongside weight loss but may also stem from direct hormonal effects.

Maintaining weight loss is significantly harder than losing it due to physiological mechanisms (AgRP neuron activation, leptin resistance) that drive weight regain, requiring sustained energy deficit and often pharmacological support.

Expect your body to fight back after you lose weight. Biological mechanisms like increased hunger signals (AgRP neurons) will try to restore your previous weight. To counter this, you need a sustained energy deficit, possibly aided by medication, and consistent lifestyle habits. Maintenance is a biological battle, not just a mental one.

Early combination therapy using low-hypoglycemia-risk agents (e.g., SGLT2 inhibitors or GLP-1 receptor agonists) combined with metformin at diagnosis is more effective than sequential stepwise therapy at maintaining glycemic targets and minimizing diabetes-related complications.

If you have just been diagnosed with Type 2 Diabetes, ask your doctor about starting with a combination of Metformin and another modern drug (like an SGLT2 inhibitor or GLP-1 agonist) right away, rather than waiting for your blood sugar to rise again. This approach keeps your blood sugar closer to normal levels for longer and protects your heart and kidneys better than starting with just one drug.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists (e.g., semaglutide, tirzepatide) produce significant weight loss (up to 24.2%) and improve metabolic parameters, but they significantly increase the risk of delayed gastric emptying and perioperative pulmonary aspiration.

If you take semaglutide or tirzepatide, tell your anesthesiologist. These drugs slow down your stomach, which increases the risk of vomiting and inhaling stomach contents during surgery, even if you feel fine. You may need to stop the drug a week before surgery, or your procedure might be delayed. Do not assume standard fasting rules are enough.

Tirzepatide improves kidney function markers (eGFR decline and albuminuria) and may slow the progression of chronic kidney disease in patients with type 2 diabetes.

Tirzepatide may help protect your kidneys by slowing the decline in kidney function and reducing protein in the urine, which is beneficial for long-term kidney health in diabetes.

GLP-1 receptor agonists (GLP-1RA) and dual GLP-1/GIP agonists significantly reduce major adverse cardiovascular events (MACE), with weight loss acting as the predominant mediator of this benefit compared to blood pressure reduction alone.

If you have type 2 diabetes or obesity and are at high cardiovascular risk, GLP-1RA medications can significantly lower your risk of heart attacks and strokes. The benefit comes largely from the weight loss these drugs cause, rather than just lowering blood pressure. Discuss these options with your doctor, especially if you have resistant hypertension.

Using ambulatory blood pressure monitoring (ABPM) instead of clinic-based measurements reveals a stronger and more consistent cardiovascular benefit from GLP-1RA therapy.

If you are on GLP-1RA therapy, ask your doctor about using ambulatory blood pressure monitoring (ABPM). It may provide a more accurate assessment of your cardiovascular risk and the effectiveness of your treatment compared to standard clinic blood pressure readings.

Higher baseline insulin sensitivity is associated with greater retention of lean mass during diet-induced weight loss, but this protective effect is nullified when aerobic or resistance exercise is included in the intervention.

If you are losing weight through diet alone, your metabolic health (insulin sensitivity) dictates how much muscle you keep; those with better sensitivity lose less muscle. However, if you add exercise (especially resistance training), your baseline insulin sensitivity no longer matters for muscle preservation. Exercise protects muscle mass regardless of your metabolic profile, making it the most reliable tool for preserving lean mass during weight loss.

Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.

Understand that GLP-1 therapy is likely a long-term commitment. If you stop taking the medication, you will likely regain most of the weight you lost. Plan for ongoing management rather than a fixed 'end date' for treatment.